Idiopathic sudden hearing loss in patients with type 2 diabetes

Fukui, Michiaki; Kitagawa, Yoshihiro; Nakamura, Naoto; Kadono, Mayuko; Mogami, Shin-ichi; Ohnishi, Masato; Hirata, Chizuko; Ichio, Naoko; Wada, Katsuya; Kishimoto, Chiyoko; Okada, Hirofumi; Miyata, Hisashi; Yoshikawa, Toshikazu

doi:10.1016/j.diabres.2003.09.013

Cited by 50 publications

(58 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…53,54 Patients with vertigo in our study had lower recovery rates compared to patients without vertigo. The presence of vertigo has been associated with a worse prognosis in several studies.…”

Section: 50-52mentioning

confidence: 49%

Metilprednisolona intratimpânica como terapia de resgate na surdez neurossensorial súbita

Raymundo¹,

Bahmad²,

Filho³

et al. 2010

Braz. j. otorhinolaryngol. (Impr.)

View full text Add to dashboard Cite

Treat ment in sudden sensorineural hearing loss is a contentious issue, today, oral steroids are the most common choice and considered the best treatment option, but the use of intratympanic steroids has become an attractive alternative, especially in cases when systemic therapy fails, or to avoid the side effects of the systemic use of steroids. Aim:To describe the results of intratympanic methylprednisolone in idiopathic sudden sensorineural hearing loss after failure of oral prednisolone.Methods: In a prospective study fourteen patients with idiopathic sudden sensorineural hearing loss were treated with intratympanic methylprednisolone after failing in the treatment with systemic steroids. Pretreatment and post-treatment audiometric evaluations including pure tone average (PTA) and speech reception thresholds (SRT) were analyzed. Results:Ten from 14 patients treated with intra-tympanic methylprednisolone presented with hearing recovery > 20 dB in PTA or 20% in SRT. Conclusion:Three intratympanic injections of methylprednisolone improved pure-tone average or speech discrimination scores for a subset of sudden hearing loss subjects that failed to benefit from oral steroids. Braz J Otorhinolaryngol. 2010;76(4):499-509. ORIGINAL ARTICLE BJORL

show abstract

Section: 50-52mentioning

confidence: 49%

Metilprednisolona intratimpânica como terapia de resgate na surdez neurossensorial súbita

Raymundo¹,

Bahmad²,

Filho³

et al. 2010

Braz. j. otorhinolaryngol. (Impr.)

View full text Add to dashboard Cite

show abstract

“…Several possible mechanisms such as microangiopathic lesions in the inner ear, auditory nerve neuropathy and even mutations in mitochondrial genes have been listed as possible causes of hearing impairment in diabetes [23]. Studies have also stressed on the need to determine the subtypes of diabetes that are at risk for hearing impairment [24]. Considering the results of this study, the high levels of creatinine in diabetic patients might explain a potential mechanism for hearing impairment in these patients.…”

Section: Discussionmentioning

confidence: 94%

The risk factors of hearing loss in diabetes mellitus

Tabatabaei¹,

Razzaghi²,

Soleimani³

et al. 2016

J Res Med Den Sci

View full text Add to dashboard Cite

Background: Hearing loss is considered as one of the complications in diabetic patients. However, studies reported conflicting results on the relationship between diabetes and hearing loss. Objectives: This study aimed to investigate and compare the prevalence of hearing loss in patients with diabetes mellitus and a group of non-diabetic people. Materials and Methods: This study was conducted on 80 patients with diabetes and 80 non-diabetic subjects. Subjects in the case group were selected among the diabetic patients registered in the diabetes centers of Isfahan province. Subjects in the control group were selected among non-diabetic individuals referring to the blood bank to donate blood. The instrument used for data collection included of questions on the subjects demographics and a special form for recording the results of the subjects' laboratory examinations including HbA1c, TSH, Cr and the result of the audiometric examinations. Data analysis was performed using descriptive statistics, chi-square test and t-test or nonparametric equivalents. Results: Compared with non-diabetic subjects, hearing loss in sounds with high frequencies was more common in patients with diabetes (P value = 0.001), the mean creatinine was significantly different in diabetic patients with and without hearing loss at noise frequencies of 4 KHz and 8 KHz (P value< 0.05). However, hemoglobin A1C, duration of diabetes and BMI were not significantly associated with hearing loss. Conclusion: Hearing impairment in high frequency sounds is more common in diabetics than healthy individuals. The severity of hearing loss in patients with diabetes is also associated with the levels of creatinine.

show abstract

“…Diabetic patients receiving steroid treatment may be at a higher risk of cardiovascular events than those receiving pentoxifylline therapy. In a study, diabetic patients with ISSNHL treated with steroids needed more frequent use of insulin for blood sugar control compared with non-diabetic patients with ISSNHL [18] . Although no acute complication such as diabetic ketoacidosis or hyperosmolar hyperglycemic state was reported in our patients during steroid therapy, close attention to blood sugar control is still necessary.…”

Section: Discussionmentioning

confidence: 99%

“…However, 1 patient in the oral group and 2 in the IV group dropped out of the study because of uncontrolled hyperglycemia. In another study, Fukui et al [18] examined clinical and audiologic characteristics of 148 ISSNHL patients, 25 (16.2%) of whom had type 2 DM. Twelve out of 17 diabetic patients who were treated with steroids needed more frequent use of insulin therapy during the treatment period for adequate blood sugar control.…”

Section: Discussionmentioning

confidence: 99%

Pentoxifylline versus Steroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss with Diabetes

2018

View full text Add to dashboard Cite

OBJECTIVES:To compare the efficacy of pentoxifylline with that of conventional steroid therapy in diabetic patients with idiopathic sudden sensorineural hearing loss (ISSNHL) and to compare blood sugar levels during hospitalization. MATERIALS and METHODS:Medical charts were retrospectively reviewed for all diabetic patients admitted to one institution for ISSNHL between 2000 and 2015. We analyzed 298 cases; 50 patients received pulse steroid treatment (steroid group) and 248 received intravenous administration of pentoxifylline only (pentoxifylline group). Hearing change was evaluated by comparing the initial hearing tests with follow-up hearing tests for up to 3 months. Blood sugar levels were also compared between the 2 groups. RESULTS:At 3 months post-treatment, the degree of hearing recovery was similar between the 2 groups. The pure-tone average was improved from baseline by 17.9±21.2 dB in the steroid group and 18.9±20.7 dB in the pentoxifylline group (p=0.776); hearing recovery rates were also similar (40% vs 39.1%; p=0.826). During hospitalization, average fasting blood sugar levels were higher (203.9±92.0 vs 174.4±54.8 mg/dL; p=0.033) and acute hyperglycemia was more common (48.0% vs 33.1%; p=0.044) with steroid versus pentoxifylline treatment. CONCLUSION:Hearing recovery rates did not significantly differ between steroid and pentoxifylline treatment in diabetic patients with ISSNHL, but pentoxifylline appeared to be associated with better blood sugar control.

show abstract

Idiopathic sudden hearing loss in patients with type 2 diabetes

Cited by 50 publications

References 15 publications

Metilprednisolona intratimpânica como terapia de resgate na surdez neurossensorial súbita

Metilprednisolona intratimpânica como terapia de resgate na surdez neurossensorial súbita

The risk factors of hearing loss in diabetes mellitus

Pentoxifylline versus Steroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss with Diabetes

Contact Info

Product

Resources

About